NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
Clinical Trials
22 trialsNCT00496756 2023-10-26
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
University of Nebraska
Phase 2 Terminated
NCT01195649 2019-06-04
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
Bayer
Terminated
NCT00727532 2019-05-03
Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Northwestern University
Phase NA Terminated
NCT00924807 2018-12-11
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
Beth Israel Medical Center
Phase 1/2 Terminated
NCT00126659 2018-11-20
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT03456401 2018-03-07
TOKIO
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT02122003 2017-11-22
SOAP
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT00714948 2015-11-16
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01342627 2015-10-06
SERCC
Centro di Riferimento Oncologico - Aviano
Phase 2 Terminated
NCT01100242 2015-09-17
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00589550 2015-06-08
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Terminated
NCT00352859 2014-12-30
Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
Bayer
Phase 4 Terminated
NCT00622479 2014-12-18
Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.
Bayer
Phase 1 Terminated
NCT00678288 2014-12-11
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
Bayer
Phase 2 Terminated
NCT00112905 2014-05-30
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00110344 2013-10-11
Research Study for Patients With Metastatic Renal Cell Carcinoma
Bayer
Phase 2 Terminated
NCT00557830 2013-07-18
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Accelerated Community Oncology Research Network
Phase 2 Terminated
NCT00098618 2013-07-02
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00452387 2011-09-16
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
Accelerated Community Oncology Research Network
Phase 2 Terminated
NCT01215266 2011-09-08
Sorafenib in Urothelium Cancer of Bladder
Association of Urologic Oncology (AUO)
Phase 2 Terminated